Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix + Poliorix
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix + Poliorix refers to the co-administration of two vaccines developed by GSK: Infanrix (a DTaP vaccine) and Poliorix (an inactivated poliovirus vaccine). Infanrix is a non-infectious sterile vaccine containing diphtheria toxoid, tetanus toxoid, and three purified pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin). Poliorix is an inactivated poliovirus vaccine (IPV) containing poliovirus types 1 (Mahoney), 2 (MEF-1), and 3 (Saukett). This combination regimen is used for primary immunization and booster doses in infants and children to provide broad protection against diphtheria, tetanus, pertussis, and poliomyelitis. The vaccines are typically administered simultaneously at separate injection sites or as part of a coordinated immunization schedule.
- Brand names
- InfanrixPoliorix
- Other names
- Infanrix-GlaxoSmithKline-poliomyelitisDTPa-IPV
02
Targets
PRN (Pertactin)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix + Poliorix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix + Poliorix.